FSGS: Causes, Symptoms, Diagnosis And Treatment

FSGS is a kidney scarring pattern with several possible causes. This guide explains symptoms, diagnosis, treatment choices and follow-up, including why the cause matters. It provides general education and cannot diagnose an individual kidney condition. [1]

What FSGS means in a kidney report

Focal segmental glomerulosclerosis, usually shortened to FSGS, describes scarring in the kidney’s microscopic filters. “Focal” means that some filters in the tissue sample are affected; “segmental” means that the scar involves part of an affected filter. The name describes an injury pattern seen in tissue, but does not establish why it happened. That distinction is central to care. People whose biopsy reports contain the same letters can have different underlying problems, treatment options and outcomes. A nephrologist, a doctor specializing in kidney disease, interprets the biopsy alongside symptoms, laboratory results and medical history before deciding what the finding means for that person. [1]

Each kidney contains many small filtering units called nephrons. A nephron includes a glomerulus, a cluster of tiny blood vessels that filters the blood, and a tubule that adjusts what returns to the circulation and what leaves as urine. Healthy filtration keeps blood cells and most large proteins in the bloodstream while allowing smaller substances through. The kidneys also help balance water and minerals and produce hormones involved in blood pressure, red blood cells and bone health. Understanding these different jobs explains why kidney assessment involves more than one test. Measuring protein leakage answers a different question from estimating filtration, and neither result alone describes every aspect of kidney health. [2]

Symptoms, protein loss and warning signs

FSGS may be discovered during tests for protein in the urine or after swelling develops. Possible symptoms include persistently foamy urine, swelling and weight gain from retained fluid. Examination may reveal high blood pressure. These findings are reasons for assessment, rather than a way to diagnose the condition at home: many kidney and non-kidney problems can produce similar changes. It helps to describe when swelling began, how quickly it changed and whether urine output changed. Bring a list of medicines and supplements to the appointment. Contact a health professional promptly for a marked decrease in urine, fever or painful urination, particularly when already receiving treatment for kidney disease. [3]

Nephrotic syndrome is a combination of heavy urinary protein loss and low blood albumin, often accompanied by swelling and increased blood fats. Albumin is a protein normally present in the blood. Losing it through injured filters can affect fluid balance and other body systems. FSGS is one possible cause of nephrotic syndrome, but the two terms are not interchangeable. Some people with an FSGS lesion have proteinuria without the full syndrome. This matters because clinicians use the complete clinical picture when classifying the disease and choosing treatment. Asking whether nephrotic syndrome is present is therefore more useful than assuming that every abnormal urine protein result has the same meaning. [4]

Why identifying the type changes treatment

FSGS categories and their implications for care [5]
Category	Clinical context	Care implication
Primary	Nephrotic syndrome; secondary and genetic explanations excluded	Specialist evaluation for immune-suppressing treatment
Secondary	An associated condition or exposure contributes to injury	Manage the cause and provide kidney-protective care
Genetic	A relevant genetic explanation is identified	Cause-specific counseling and treatment decisions
Undetermined cause	No cause established and no nephrotic syndrome	Supportive care and reassessment; avoid automatic immune suppression

Secondary FSGS develops in association with another process that injures or places extra demand on the filters. The assessment may consider infections, exposure to certain medicines or drugs, and conditions that increase stress on functioning kidney tissue. A history of reduced kidney tissue or other kidney abnormalities can be relevant. The clinical task is to identify which explanation actually fits, rather than attaching blame to a single risk factor. If a contributing condition is identified, treating or managing that condition becomes part of kidney care. A medicine review should include prescribed treatments, nonprescription products and supplements. Do not stop a useful prescription on the basis of a suspected association without discussing it with the prescriber. [6]

A genetic explanation can change the interpretation of FSGS, including expectations about immune-suppressing medicines and implications for relatives. Testing may be particularly useful when kidney disease starts young, several family members are affected, other features suggest an inherited syndrome, or the clinical course is unusual. A genetic test is not simply a yes-or-no test for all kidney disease. Results may identify a relevant change, be negative or remain uncertain. Counseling helps explain what a result can and cannot establish, whether relatives might benefit from assessment and how information will be used. Decisions about testing should include its possible benefits, limits, cost and privacy implications, rather than treating it as an automatic requirement for everyone. [7, 41]

APOL1 is one gene associated with increased risk of certain kidney diseases, including forms that can show FSGS on biopsy. Particular risk variants are more common in people with recent ancestry from parts of Africa, but ancestry and self-described race do not reveal a person’s genotype. Having risk variants also does not mean that kidney disease is inevitable. This distinction matters when reading population statistics or considering testing. A result needs clinical interpretation alongside the person’s kidney findings and family history. Genetic information may become relevant to research participation and donor discussions, but it should not be used to assume that every person from a particular background has the same cause of kidney disease. [8]

How the diagnosis is built from several kinds of evidence

The diagnostic workup begins with the history, examination and basic blood and urine results. A clinician considers previous kidney measurements, blood pressure, other illnesses and the time course of the problem. Additional tests are selected to investigate plausible causes rather than ordered as a universal checklist. Depending on the findings, these may include tests for infections or immune conditions and imaging of the kidneys. An ultrasound can provide structural information but cannot identify microscopic FSGS scarring by itself. Copies of earlier laboratory results are valuable because a newly discovered abnormality may have existed for some time. Establishing the cause matters even when another condition, such as diabetes or hypertension, is already present. [9]

Urine testing measures the amount of protein escaping through the kidneys. An albumin-to-creatinine ratio, often written UACR or ACR, compares albumin with creatinine in a urine sample; the comparison helps account for how dilute the sample is. Clinicians may also measure total protein using a protein-to-creatinine ratio or a timed collection. These are related tests, but they do not all report the same substance or use interchangeable units. Ask which measurement is being followed and compare like with like. A single result may need confirmation, particularly if a temporary illness or other circumstance could affect it. Trends help show whether protein leakage is improving, persisting or increasing. [10, 40]

Estimated glomerular filtration rate, or eGFR, is calculated from blood markers to estimate kidney filtration. Creatinine is commonly used; cystatin C can sometimes add useful information. The result is an estimate, with limitations related to the marker, the equation and the person being assessed. A small change should be interpreted in context rather than treated as a precise count of functioning filters. Clinicians may confirm unexpected results or use additional measurements when a decision requires greater accuracy. Protein leakage and eGFR should be considered together: substantial protein loss can exist even when filtration is relatively preserved. Conversely, a fall in filtration requires assessment even if a person does not notice worsening swelling. [11]

A kidney biopsy removes a small tissue sample so that a pathologist can examine it for evidence of disease and damage. It may clarify a cause that blood tests, urine tests and imaging cannot establish. The team explains why it is being proposed, how to prepare, and its benefits and risks, including bleeding. Tell them about medicines and products that could affect bleeding, and follow their specific preparation instructions. Afterward, observation and activity advice are individualized. A biopsy can guide treatment, but the report still needs discussion in the context of the wider assessment. Ask what the sample showed, what remains uncertain and whether the result changes the next decision. [12]

The appearance of the filtering cells is important but cannot settle every diagnostic question. A report may describe podocytes, specialized cells that help maintain the filtration barrier, and “foot process effacement,” a change in their fine extensions. Even widespread effacement is not unique to primary FSGS. Reading that phrase in isolation should not lead directly to a conclusion that steroids are necessary. Similarly, a label such as “not otherwise specified” describes a pathology category, not a complete explanation of the illness. Nephrologists reconcile the tissue findings with albumin levels, protein loss and possible causes. If the clinical picture changes substantially, further evaluation or, in selected cases, repeat biopsy may be considered. [13]

Treatment goals and medicines

A treatment plan usually has several goals: protect kidney function, reduce protein loss where possible, control blood pressure, relieve troublesome fluid retention and limit complications. Follow-up tests help determine whether the plan is helping and whether medicines are causing problems. It is useful to know which result each treatment is meant to improve, when it will be checked and whom to contact between appointments. Access, cost and side effects can affect whether a plan is practical, so these belong in the discussion. Keeping a current medicine list and sharing it across the care team reduces confusion. Treatment decisions are revisited as laboratory results, other health conditions and personal circumstances change. [14]

When immune suppression may help

For appropriately classified primary FSGS, immune-suppressing treatment may be considered by a nephrologist. KDIGO guidance describes glucocorticoids as an initial option and calcineurin inhibitors, such as tacrolimus or cyclosporine, in selected circumstances, including steroid resistance or intolerance. These choices require assessment of likely benefit, risks and monitoring needs. The same approach should not be applied automatically to secondary FSGS or FSGS of undetermined cause. Genetic disease also requires a cause-specific assessment rather than assuming immune suppression will help. When a presumed primary case responds poorly or treatment is not tolerated, reassessing the diagnosis and seeking specialist-center input may be more useful than repeatedly escalating medicines. The decision is not determined by the biopsy label alone. [5]

Glucocorticoids can affect many systems beyond the kidney. Potential problems include infection risk, changes in sleep and mood, and effects on bones with prolonged exposure. A monitoring plan should therefore address more than the urine protein result. People may need advice about infection exposure, vaccines, bone health and other medicines, depending on their situation. Report troublesome effects early so that the team can weigh them against the response to treatment. Do not abruptly stop a prescribed steroid or change a taper without professional advice. Understanding why a medicine was selected and how the team will judge its effectiveness can make a difficult course of treatment easier to discuss. [15]

Reducing protein loss and protecting the kidneys

ACE inhibitors and angiotensin receptor blockers, often called ARBs, are commonly used to reduce pressure within the kidney’s filtering system and lower urine albumin loss. They can be useful even when the main reason for treatment is kidney protection rather than a very high blood pressure reading. Selection depends on the wider clinical picture. Blood pressure, potassium and kidney function need monitoring, especially after treatment begins or changes. Dizziness, dehydration or an unexpected laboratory change should prompt a discussion rather than an unsupervised adjustment. These medicines are not interchangeable with every other blood pressure drug, and combining an ACE inhibitor with an ARB is generally avoided. Pregnancy plans also need review because these treatments can harm a developing baby. [16]

The U.S. treatment landscape changed in April 2026. The FDA approved sparsentan, sold as Filspari, to reduce proteinuria in adults and children aged eight years and older with FSGS without nephrotic syndrome. This is a specific indication, not a treatment recommendation for everyone whose biopsy says FSGS. The FSGS indication concerns proteinuria reduction; it should not be described as proof that the medicine prevents kidney failure in this population. The label carries boxed warnings for liver toxicity and harm to a developing baby, and access involves a restricted REMS safety program. Liver monitoring, pregnancy precautions where relevant, and review of kidney function, potassium, blood pressure and interacting medicines are essential. It must not simply be added to an existing ARB or certain other medicines. A nephrologist must assess eligibility, the complete medication plan and applicable local approval and availability. [17]

Treatment evidence needs to be read by outcome as well as by headline. In the randomized DUPLEX trial, sparsentan produced a greater reduction in proteinuria than the comparator, irbesartan, but the main analysis did not show a statistically significant difference in the rate of eGFR decline over the trial period. That distinction explains why a reduction in urinary protein and a demonstrated long-term kidney benefit should not be treated as identical claims. Trial participants also met specific entry criteria, so results do not automatically apply to every FSGS subtype or age group. When discussing a new medicine, ask what benefit was measured, who was studied and what remains uncertain. [18]

SGLT2 inhibitors are another class that may be considered for selected people with chronic kidney disease, including people without diabetes. Whether they fit an individual with FSGS depends on kidney function, albuminuria, other illnesses and the full treatment plan. Broad CKD recommendations do not establish that every person with an FSGS lesion should receive the same medicine. Clinicians discuss possible adverse effects and circumstances, such as fasting, surgery or serious illness, when a temporary interruption may be needed under a clear plan. These medicines also do not replace the work of determining the cause of FSGS. Ask the prescriber which kidney-protection evidence applies to the individual situation and what monitoring is required. [19]

FSGS-specific evidence for SGLT2 inhibitors has important limits. A prespecified DAPA-CKD analysis included a relatively small group with biopsy-confirmed FSGS. Some measurements favored dapagliflozin, but few participants reached the principal clinical outcome, and the uncertainty around that result was wide. Such a subgroup can add useful information without providing a definitive answer for every type of FSGS. This is particularly relevant when different mechanisms of injury are grouped under one pathology label. The practical implication is to combine broader CKD evidence with the person’s diagnosis and risk profile. A promising subgroup finding should not become a guarantee of benefit, and a small study should not be read as if it settled every remaining question. [20]

Food, fluid and everyday medicine safety

There is no single eating plan that suits every person with FSGS. Nutritional needs depend on kidney function, laboratory results, swelling, appetite, other illnesses and whether dialysis is needed. Losing protein in urine does not mean that an unrestricted high-protein diet will repair the filters. Equally, severe self-imposed restriction can make it difficult to meet energy and nutritional needs. A kidney dietitian can help choose appropriate amounts and sources of protein while keeping meals practical. Potassium and phosphorus restrictions are not automatic for everyone; the need depends on the clinical situation. Bring food preferences, cultural staples and budget constraints into the discussion so that any changes can be sustained without unnecessarily narrowing the diet. [21]

Sodium deserves attention because it can contribute to thirst, fluid retention and higher blood pressure. Much of it comes from packaged foods, restaurant meals, sauces and other prepared products rather than only the salt added at the table. Reading labels and comparing similar products can make changes more manageable. The care team can recommend an appropriate target based on the person’s health and treatment. A “low-sodium” substitute is not automatically suitable: some contain potassium, which may be a concern with reduced kidney function or certain medicines. Ask a dietitian or pharmacist before adopting a substitute. The aim is a workable plan that supports fluid and blood pressure management while preserving adequate nutrition. [22]

Fluid advice must also be individualized. Swelling does not mean that everyone should use the same drinking limit, and drinking large amounts of water does not flush FSGS scars away. Too little fluid can lead to dehydration, while too much can be harmful when the kidneys cannot remove it adequately. Ask the care team whether any limit is needed and what amount is appropriate. Advice may change with kidney function, urine output, illness and treatment. An instruction found online for a person receiving dialysis may not fit someone with preserved filtration. Understanding the reason for a recommendation helps avoid both forced hydration and unnecessary restriction. Review the plan when circumstances change. [23]

Nonprescription products can matter as much as prescription medicines. NSAID pain relievers can injure the kidneys, particularly during dehydration or when combined with other medicines that affect kidney blood flow. Ask a clinician or pharmacist about suitable pain relief and check combination cold or pain products rather than relying only on a brand name. Vomiting, diarrhea or poor fluid intake can change the safety of an otherwise stable medication plan. Agree in advance whom to call and whether any medicines should be temporarily adjusted during illness. Bring supplements and herbal remedies into the review too. A product marketed as a kidney cleanse should not be assumed to protect the kidneys or replace treatment. [24]

Complications and follow-up that deserve attention

Nephrotic syndrome can have consequences beyond swelling. Changes in blood proteins and fats can increase the risk of blood clots, infection and cardiovascular problems, while severe protein loss may affect nutritional status. The presence and severity of these problems vary. A clinician may consider cholesterol treatment or other preventive measures according to the overall risk profile. Blood-thinning treatment is not a universal instruction for everyone with FSGS: possible benefit must be balanced against bleeding risk and individual circumstances. Diuretics may help remove excess fluid, with appropriate monitoring. At follow-up, discuss symptoms as well as numbers, including fatigue, swelling and infection concerns. Improvement in visible swelling does not replace laboratory monitoring of protein loss and kidney function. [25]

A blood clot in a deep vein may cause new swelling, tenderness, warmth or discoloration, often in one limb. A clot that travels to the lungs can cause sudden breathlessness, chest pain, a fast heartbeat, coughing blood or fainting. These symptoms need urgent assessment; severe or sudden breathing or chest symptoms warrant emergency help. Do not wait to prove that the symptoms are related to kidney disease. People taking anticoagulants also need clear instructions about bleeding and interactions. The purpose of knowing warning signs is to respond promptly, not to diagnose a clot from a symptom list. Many symptoms have more than one possible cause, and testing determines the explanation. [26, 27]

Vaccination planning is part of care when kidney disease or immune-suppressing treatment increases infection risk. Which vaccines are appropriate depends on age, previous vaccinations, the medicines being used and local recommendations. Some vaccines work less well during substantial immune suppression, and live vaccines may be unsuitable in that setting. This makes timing a discussion to have before treatment when possible, rather than after an exposure occurs. Keep a record of immunizations and tell every clinician about immune-suppressing medicines. Ask what to do after contact with a significant infection and how quickly fever should be reported. A vaccine plan should be personalized; an online list cannot account for the full treatment history. [28]

The outlook cannot be predicted from the letters FSGS alone. Kidney function at diagnosis, degree and persistence of protein loss, and response to treatment all matter. Research cohorts have found that achieving a reduction in proteinuria, including remission, is associated with better kidney outcomes. Association does not promise the same course for every individual, and remission does not necessarily mean that existing scar tissue has disappeared. Ask the nephrologist how response is defined in the current plan and what pattern would lead to a change. A useful discussion focuses on trends and remaining uncertainty rather than a fixed deadline for dialysis or a guaranteed recovery percentage. [29]

FSGS in children and family life

Children with nephrotic syndrome need a pediatric approach. The likely causes, initial assessment and response to treatment differ from those in adults; not every child requires the same investigations at the same point. Growth, nutrition, infection prevention, schooling and medicine effects all need attention. Parents or caregivers may be taught to monitor urine or swelling, but the schedule and thresholds should come from the child’s team. Keep instructions clear about whom to contact during illness and which changes need prompt review. A child’s response to treatment helps guide further investigation, including possible biopsy or genetic testing. Adult diet restrictions and medicine advice should not be transferred to a child without pediatric kidney guidance. [30, 31]

Long-term kidney care can affect school, work, sleep, relationships and emotional well-being. Repeated appointments and uncertainty may be demanding even when someone looks well. Practical support can include a social worker, counseling, school planning or help addressing treatment costs and transport. Families benefit from knowing who coordinates information and how to reach the kidney team between visits. For children, involving them in age-appropriate explanations and routines can support growing independence without placing the entire burden on them. Describe difficulties with treatment openly: a plan that cannot be followed needs adjustment. Emotional support is part of living with kidney disease and can sit alongside, rather than compete with, medical care. [32, 33]

If kidney function declines: planning and transplantation

Some people with FSGS eventually develop kidney failure, while others retain useful function for many years. If decline becomes advanced, discussing treatment options early allows time to consider dialysis, transplantation and, where appropriate, conservative kidney management. The choice depends on health, goals and the expected benefits and burdens of treatment. Dialysis decisions are based on the overall clinical situation, not solely on a number read online. Learning about options does not mean that dialysis must start immediately. It gives the person and their family time to understand how different approaches may affect daily life. A nephrology team can explain when education, access planning or transplant evaluation becomes relevant. [34]

A kidney transplant can provide kidney function for a suitable person with kidney failure, but it involves a substantial evaluation and continuing care. Recipients need medicines to prevent rejection and monitoring for complications. The transplant team assesses the original cause of kidney disease, other health conditions and donor considerations. A living donor also needs an independent evaluation, and a family relationship does not establish that donation is safe. When inherited disease is possible, genetic information may be relevant to that assessment. Transplantation is therefore a treatment pathway with preparation and long-term responsibilities. It should not be described as a guaranteed cure for every person who has an FSGS diagnosis. [35]

Primary FSGS can recur in a transplanted kidney, which is one reason careful classification before transplantation matters. The TANGO observational study examined recurrence in a selected group of adults with idiopathic FSGS. Its findings should not be applied automatically to all secondary or genetic forms. Differences in how studies define FSGS also affect reported rates, making a single universal percentage misleading. An individual discussion considers the original presentation, prior transplant history and any genetic findings. After transplantation, monitoring for proteinuria helps the team detect a possible recurrence promptly. Neither assuming recurrence is inevitable nor assuming a new kidney eliminates the risk gives an accurate picture. [36]

Research and useful questions for the next appointment

Clinical studies may investigate new treatments, genetic mechanisms, markers of disease activity or ways to improve quality of life. Eligibility can depend on the FSGS category, age, kidney function, proteinuria and medicines already being taken. A registry entry is a starting point for discussion, not evidence that an experimental treatment is effective or appropriate. Ask what the study is trying to learn, how participation differs from usual care, what risks and visits are involved, and whether travel or other costs are covered. Participation should be voluntary and based on informed consent. The kidney team can help interpret a study alongside established options, including whether taking part would require changes to current treatment. [37]

A productive follow-up appointment connects results to decisions. Ask which urine measurement is being tracked, what the latest filtration estimate means, and whether the changes fit the expected response. Keep results with their dates and units rather than comparing isolated numbers from different tests. Clarify when the next blood and urine checks are due and who will review them. If the cause remains uncertain, ask what additional finding would change that assessment. It is also reasonable to request a written explanation of the treatment goals, warning signs and contact plan. Understanding what is being monitored makes it easier to recognize progress, identify side effects and take part in decisions over time. [38]

Frequently asked questions about FSGS

What does FSGS stand for?

FSGS stands for focal segmental glomerulosclerosis, a pattern of scarring affecting parts of some kidney filters. Its cause requires further assessment. [1]

Can a urine test diagnose FSGS?

Urine tests reveal protein loss but cannot identify the FSGS scarring pattern. Clinicians combine the assessment with kidney biopsy when appropriate. [12]

Does everyone with FSGS have nephrotic syndrome?

No. Some people have proteinuria without the full nephrotic syndrome. That distinction helps guide classification and treatment. [4]

Does every FSGS diagnosis need steroids?

No. Steroids may help selected primary FSGS cases, but a biopsy label alone does not justify them. The cause and clinical findings matter. [13]

Is FSGS always inherited?

No. Some forms have a genetic cause, while others do not. Selected people may benefit from genetic testing and counseling. [7]

Can FSGS return after a kidney transplant?

Primary FSGS can recur after transplantation. Risk depends on the underlying disease, so a transplant team should discuss the individual situation. [36]

Sources

References checked 7 October 2026. Guidance and medicine approvals can change; individual care requires current professional advice.

FSGS (Focal Segmental Glomerulosclerosis): Causes, Diagnosis and Treatment